Everything journalists need to cover The Reversal Initiative. Story angles, assets, and direct contact information.
The Reversal Initiative is a self-funded computational-biology initiative building AI-powered drug-discovery tools to fight Alzheimer's disease. Founded by David Scott Lewis (former META EVP, 20+ peer-reviewed papers) and Enrique Zueco (CTO), the initiative offers a 37-module computational platform to academic and foundation-funded research partners under partnership-access terms — at no cost to qualified labs.
The project follows the Pieper lab's 2025 Cell Reports Medicine paper (DOI: 10.1016/j.xcrm.2025.102535) from Case Western Reserve / Harrington Discovery Institute, which demonstrated that P7C3-A20, an NAD+ pathway activator, reversed Alzheimer's pathology in mice. The Reversal Initiative builds the computational bridge between preclinical breakthroughs like this one and potential human therapies — across multiple AD compounds and pathways.
The team has published 22+ peer-reviewed biology papers, including 7 Alzheimer-specific papers at ICLR 2026 across genomics, drug-discovery, and biomedical-reasoning workshops, and prior work at AAAI-26 and NeurIPS. The platform is designed for academic and foundation-funded research partners who cannot afford enterprise computational platforms.
A tech executive's mother died from Alzheimer's. His sister was diagnosed 18 months ago. Now he's building the tools he wishes existed.
Scientists reversed Alzheimer's in mice. A European computational-biology team is building the bridge to human therapies through a 37-module platform offered to academic and foundation-funded research partners.
A grassroots campaign to democratize drug discovery. For 25 euros, you can screen 5,000 molecules against Alzheimer's targets.
Why locking research tools behind $500K enterprise contracts slows down the fight against the world's most costly disease — and what a partnership-access model can change.
How AI-powered computational tools, offered under partnership-access terms, can give academic and foundation-funded labs the kind of capability once reserved for big pharma.
High-resolution founder photos and team imagery (coming soon)
Initiative and AIXC logos in SVG, PNG, and EPS formats (coming soon)
Single-page summary with key facts and figures (coming soon)
For interviews, comments, or additional information:
We typically respond to press inquiries within 12 hours.
Get the complete media package including high-res assets, fact sheet, founder bios, and interview availability.
Request Press Kit